Pharma-Bio Serv Revenue Falls 7.1% to $2.3M in Q1 FY2026

Pharma-Bio Serv, Inc., a pharmaceutical services company, reported revenue of $2.29 million for the three months ending January 31, 2026, a decline of 7.1% from $2.47 million in the same period a year earlier. The company posted a net profit of $32,860, up from $8,536 in the first quarter of fiscal 2025. Read more earnings reports.

Despite the revenue decline, the company improved its bottom line. Operating loss narrowed slightly to $94,535 from $92,191 a year earlier. Other income totaled $131,025, compared to $101,842 in the prior-year quarter, helping drive profitability.

Gross profit for the quarter came in at $722,374, down from $768,109 a year earlier. Cost of revenue decreased to $1.57 million from $1.70 million. Selling, general and administrative expenses fell to $816,909 from $860,300 in the year-ago period.

Cash and restricted cash stood at $5.76 million as of January 31, 2026, up from $3.38 million as of October 31, 2025, but below the $7.31 million reported at the end of January 2025. The company used $390,139 in operating activities during the quarter, compared to $429,486 used in the year-ago period.

Cash from investing activities totaled $2.77 million, sharply higher than $988,338 in the prior-year quarter. Cash from financing was negligible, with $1,681 used in the quarter compared to no activity a year earlier.

Total assets decreased to $13.55 million as of January 31, 2026, from $13.65 million at the end of October 2025. Current assets were $13.32 million, down from $13.39 million. Accounts receivable increased to $2.65 million from $2.36 million.

Total liabilities nearly doubled to $3.31 million from $1.74 million at the end of the prior quarter, all classified as current liabilities. Stockholders' equity fell to $10.24 million from $11.91 million as of October 31, 2025. Retained earnings declined to $8.85 million from $10.53 million.

The company reported diluted earnings per share of $0.001 for the quarter, compared to $0.000 in the year-ago period. Weighted average diluted shares outstanding were 22.91 million, down slightly from 22.96 million a year earlier.